Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SHR1459 + YY-20394
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SHR1459 + YY-20394 is an oral combination therapy being investigated for recurrent and refractory B-cell non-Hodgkin's lymphoma. SHR1459 is a Bruton’s tyrosine kinase (BTK) inhibitor, while YY-20394 (also known as linperlisib) is a highly selective phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor. The combination is designed to target two key signaling pathways involved in B-cell malignancy survival and proliferation. Clinical trials are evaluating its safety and efficacy in patients whose disease is resistant to prior therapies[3][4][10].
- Other names
- SHR1459 + YY-20394SHR1459 plus YY-20394SHR-1459 plus YY-20394SHR 1459 plus YY-20394SHR1459 combined with YY-20394SHR-1459 combined with YY-20394SHR 1459 combined with YY-20394
02
Targets
PIK3CD (Phosphatidylinositol 3-kinase delta)BTK (Bruton tyrosine kinase)
Beyond the preview
Go deeper on SHR1459 + YY-20394.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SHR1459 + YY-20394.